



**30th March 2022**

**ASX ANNOUNCEMENT**

**InhaleRx Ltd (“IRX”) granted wholesale licences to sell and supply Poisons Or Controlled Substances, including medicinal cannabis.**

InhaleRx Limited (ASX: IRX) is pleased to announce that the Victorian Department of Health & Human Services (“DHHS”) has granted the Company licences under the Drugs, Poisons and Controlled Substances Act 1981.

The Licences authorise IRX to wholesale scheduled substances, including all Schedule 2, 3, and 4 medications, as well as, limited Schedule 8 medications which includes medicinal cannabis.

IRX will store and distribute these medications using accredited third party logistics suppliers to authorised recipients nationally.

Executive Director, Darryl Davies advised,

“Receipt of the relevant licences to supply scheduled medications is an important milestone for IRX and supports our mid to long term objectives.

Given this development, the Company can now take ownership of scheduled medications which creates possibilities for new product development and associated revenue streams.

The Company also achieves supply chain efficiencies for procurement of Cannabidiol (CBD) and Dronabinol (THC) which are both required for each of its planned clinical trial programmes without the need to involve third-parties”.

Approved by the Board of Directors.

**For further information:**

Nova Taylor  
Company Secretary  
(03) 8678 4091

***About InhaleRx Limited (ASX: IRX) – [www.inhalerx.com.au](http://www.inhalerx.com.au)***

InhaleRx Limited is an Australian healthcare and technology company which is focused on developing inhalation therapies. The Company currently markets the Medihale inhalation device and is working on developing a range of inhaled therapeutic medicinal formulations for registration domestically and internationally.